Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety

An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material

“…The present efficacy data are in line with those from numerous clinical trials with fesoterodine , including studies on patient‐reported outcomes , long‐term studies and dedicated studies in elderly people . Moreover, the overall improvement of patient‐reported outcomes PPBC and PPUS is comparable with those reported previously from observational studies with other muscarinic receptor antagonists including tolterodine or solifenacin .…”

“…The incidence of treatment‐emergent AEs in this study was considerably lower than in controlled studies with fesoterodine or other muscarinic antagonists . However, the qualitative spectrum of mostly dry mouth and constipation was in line with those studies.…”

“…In contrast, the efficacy and safety of muscarinic receptor antagonists as a class has been well documented in numerous controlled trials . Fesoterodine is the most recent addition to this class, and its efficacy and safety have also been documented in many controlled studies , including long‐term studies , studies on patient‐reported outcomes and dedicated studies in elderly people .…”

The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study

“…The tarafenacin 0.2 mg group was identified to be superior to the placebo group in the mean change of the number of micturitions per 24 h from baseline to 4 weeks. Clinical trials for other anticholinergics such as solifenacin or fesoterodine have reported of their efficacy of mean change micturition per 24 h from baseline −1.6 to −3.0 with fesoterodine (4 and 8 mg) and −1.9 to 2.8 with solifenacin (5 and 10 mg) in some meta‐analyses . In this study, tarafenacin has shown a similar efficacy when compared with them.…”

“…Interestingly, the incidence rate of constipation was remarkably less than that for the other antimuscarinic drugs. The reported incidence rates of constipation were 15.1% with oxybutynin , 6% with tolterodine , 4% with 4 mg and 6% with 8 mg in fesoterodine fumarate , 5.4% with 5 mg and 13.4% with 10 mg with solifenacin , 5.8% with trospium chloride , 14.8% with 7.5 mg and 21.3% with 15 mg with darifenacin . The rate of constipation of tarafenacin in this study is comparatively lower than that of other equivalent alternative anticholinergic agents.…”